Evidence map›Paper›PMID 31644357›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer.

Douglas G McNeel, Jens C Eickhoff, Laura E Johnson, Alison R Roth, Timothy G Perk, Lawrence Fong, Emmanuel S Antonarakis, Ellen Wargowski, Robert Jeraj, Glenn Liu

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01341652 (Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase), which is not on this map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01341652 phase2completednot on this map

Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2011 to 2020Enrolled99ConditionsProstate CancerArmspTVG-HP, rhGM-CSF
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Douglas G McNeelUniversity of Wisconsin, Madison, WI.
Jens C EickhoffUniversity of Wisconsin, Madison, WI.
Laura E JohnsonUniversity of Wisconsin, Madison, WI.
Alison R RothUniversity of Wisconsin, Madison, WI.
Timothy G PerkUniversity of Wisconsin, Madison, WI.
Lawrence FongUniversity of California, San Francisco, San Francisco, CA.
Emmanuel S AntonarakisJohns Hopkins University, Baltimore, MD.
Ellen WargowskiUniversity of Wisconsin, Madison, WI.
Robert JerajUniversity of Wisconsin, Madison, WI.
Glenn LiuUniversity of Wisconsin, Madison, WI.
University of Wisconsin–Madison · USJohns Hopkins University · USUniversity of California, San Francisco · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

purposeWe previously reported the safety and immunologic effects of a DNA vaccine (pTVG-HP [MVI-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent, nonmetastatic prostate cancer. The current trial evaluated the effects of this vaccine on metastatic progression. PATIENTS AND

methodsNinety-nine patients with castration-sensitive prostate cancer and prostate-specific antigen (PSA) doubling time (DT) of less than 12 months were randomly assigned to treatment with either pTVG-HP co-administered intradermally with 200 μg granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant or 200 μg GM-CSF alone six times at 14-day intervals and then quarterly for 2 years. The primary end point was 2-year metastasis-free survival (MFS). Secondary and exploratory end points were median MFS, changes in PSA DT, immunologic effects, and changes in quantitative

resultsTwo-year MFS was not different between study arms (41.8% vaccine

conclusionpTVG-HP treatment did not demonstrate an overall increase in 2-year MFS in patients with castration-sensitive prostate cancer, with the possible exception of a subgroup with rapidly progressive disease. Prespecified

Indexed as

Acid PhosphataseAdenocarcinomaAgedAged, 80 and overCancer VaccinesDisease ProgressionDouble-Blind MethodHumansMaleMiddle AgedProgression-Free SurvivalProstatic NeoplasmsVaccines, DNAAcid PhosphataseCancer Vaccinesprostatic acid phosphataseVaccines, DNA

Identifiers

PMID31644357
PMCPMC7194451
OpenAlexW2982242906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.